Effect of Acute Changes of Serum Phosphate on Fibroblast Growth Factor (FGF)23 Levels in Humans

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2007 Oct 31

PMID 17968495

Citations 60

Authors

Nobuaki Ito

Seiji Fukumoto

Yasuhiro Takeuchi

Shu Takeda

Hisanori Suzuki

Takeyoshi Yamashita

Toshiro Fujita

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor (FGF)23 was identified as a humoral factor involved in the development of several hypophosphatemic diseases. Subsequent studies indicated that FGF23 is a hormone regulating serum phosphate level. However, it is still unknown how the production and serum level of FGF23 are regulated. This study was designed to determine whether acute changes of serum phosphate modulate FGF23 levels in human. Four healthy volunteers participated in the study. In the phosphate infusion study, dibasic potassium phosphate was infused at a rate of 10 mEq/h for 4 h, and serum FGF23 levels were measured for up to 6 h after the start of the infusion. In the carbohydrate study, partially hydrolyzed starch corresponding to 150 g glucose was ingested and FGF23 levels were measured similarly for 6 h. Phosphate infusion significantly increased and carbohydrate ingestion decreased serum phosphate levels, respectively. However, FGF23 did not change by these maneuvers. It is concluded that acute changes of serum phosphate do not modify FGF23 levels in the healthy human.

Citing Articles

Young adults' circulating FGF23 and α-klotho and their relationship with habitual dietary acid load and phosphorus intake during growth.

Franco L, Derakhshandeh-Rishehri S, Nothlings U, Hartmann M, Herder C, Kalhoff H Sci Rep. 2024; 14(1):27784.

PMID: 39537770 PMC: 11561314. DOI: 10.1038/s41598-024-79636-0.

Organic phosphate but not inorganic phosphate regulates expression through MAPK and TGF-ꞵ signaling.

Ratsma D, Muller M, Koedam M, van Leeuwen J, Zillikens M, van der Eerden B iScience. 2024; 27(6):109625.

PMID: 38883842 PMC: 11178987. DOI: 10.1016/j.isci.2024.109625.

FGF23 and klotho at the intersection of kidney and cardiovascular disease.

Edmonston D, Grabner A, Wolf M Nat Rev Cardiol. 2023; 21(1):11-24.

PMID: 37443358 DOI: 10.1038/s41569-023-00903-0.

Focusing on Phosphorus Loads: From Healthy People to Chronic Kidney Disease.

Wang M, Zhang J, Kalantar-Zadeh K, Chen J Nutrients. 2023; 15(5).

PMID: 36904234 PMC: 10004810. DOI: 10.3390/nu15051236.

Impact of X-Linked Hypophosphatemia on Muscle Symptoms.

Romagnoli C, Iantomasi T, Brandi M Genes (Basel). 2022; 13(12).

PMID: 36553684 PMC: 9778127. DOI: 10.3390/genes13122415.

References

Weber T, Liu S, Indridason O, Quarles L . Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003; 18(7):1227-34. DOI: 10.1359/jbmr.2003.18.7.1227. View

Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B . Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38(11):1310-5. PMC: 1839871. DOI: 10.1038/ng1905. View

Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama J, Shimada T . Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004; 151(1):55-60. DOI: 10.1530/eje.0.1510055. View

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T . Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-60. DOI: 10.1210/jc.2002-021105. View

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T . Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005; 289(5):F1088-95. DOI: 10.1152/ajprenal.00474.2004. View

Chefetz I, Heller R, Galli-Tsinopoulou A, Richard G, Wollnik B, Indelman M . A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet. 2005; 118(2):261-6. DOI: 10.1007/s00439-005-0026-8. View

Jonsson K, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y . Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348(17):1656-63. DOI: 10.1056/NEJMoa020881. View

Gupta A, Winer K, Econs M, Marx S, Collins M . FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004; 89(9):4489-92. DOI: 10.1210/jc.2004-0724. View

Benet-Pages A, Orlik P, Strom T, Lorenz-Depiereux B . An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2004; 14(3):385-90. DOI: 10.1093/hmg/ddi034. View

10.

Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson K . Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64(6):2272-9. DOI: 10.1046/j.1523-1755.2003.00328.x. View

11.

Shigematsu T, Kazama J, Yamashita T, Fukumoto S, Hosoya T, Gejyo F . Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004; 44(2):250-6. DOI: 10.1053/j.ajkd.2004.04.029. View

12.

Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T . Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab. 2004; 89(8):3979-82. DOI: 10.1210/jc.2004-0406. View

13.

Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N . A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab. 2005; 90(10):5523-7. DOI: 10.1210/jc.2005-0301. View

14.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561-8. PMC: 338262. DOI: 10.1172/JCI19081. View

15.

. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View

16.

Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A . FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004; 65(5):1943-6. DOI: 10.1111/j.1523-1755.2004.00604.x. View

17.

Perwad F, Azam N, Zhang M, Yamashita T, Tenenhouse H, Portale A . Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005; 146(12):5358-64. DOI: 10.1210/en.2005-0777. View

18.

Sitara D, Razzaque M, Hesse M, Yoganathan S, Taguchi T, Erben R . Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23(7):421-32. PMC: 2894977. DOI: 10.1016/j.matbio.2004.09.007. View

19.

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S . Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98(11):6500-5. PMC: 33497. DOI: 10.1073/pnas.101545198. View

20.

Larsson T, Yu X, Davis S, Draman M, Mooney S, Cullen M . A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab. 2005; 90(4):2424-7. DOI: 10.1210/jc.2004-2238. View